Treatment of Gorlin syndrome (nevoid basal cell carcinoma syndrome) with methylaminolevulinate photodynamic therapy in seven patients, including two children: interest of tumescent anesthesia for pain control in children

Girard, Christian; Debu, A.; Bessis, Didier; Blatiere, Véronique; Dereure, O.; Guillot, B.

doi:10.1111/j.1468-3083.2012.04538.x

Cited by 24 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean Tmax without liposuction was 13.1 hours (range, 8-24), which was not significantly different from the mean Tmax with liposuction 12.5 hours (range, [8][9][10][11][12][13][14][15][16][17][18]; P = 0.19).…”

Section: Resultsmentioning

confidence: 88%

Estimated Maximal Safe Dosages of Tumescent Lidocaine

Klein

Jeske

2016

Survey of Anesthesiology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 88%

Estimated Maximal Safe Dosages of Tumescent Lidocaine

Klein

Jeske

2016

Survey of Anesthesiology

View full text Add to dashboard Cite

“…Gorlin syndrome (naevoid basal cell carcinoma syndrome) is an autosomal dominant mutation of the PTCH-1 gene of the hedgehog signaling pathway, resulting in multiple early BCCs [88]. Surgical excision is the traditional gold standard of treatment, with the potential for significant scarring and disfigurement [89].…”

Section: Gorlin Syndromementioning

confidence: 99%

“…Several small studies have supported the use of MAL-PDT for patients with Gorlin syndrome. Favourable cosmetic results have been achieved, with complete clearance in many cases [88,89,90,91,92,93]. …”

Section: Gorlin Syndromementioning

confidence: 99%

See 1 more Smart Citation

Photodynamic Therapy and Non-Melanoma Skin Cancer

Griffin

Lear

2016

Cancers

View full text Add to dashboard Cite

Non-melanoma skin cancer (NMSC) is the most common malignancy among the Caucasian population. Photodynamic therapy (PDT) is gaining popularity for the treatment of basal cell carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK). A topical or systemic exogenous photosensitiser, results in selective uptake by malignant cells. Protoporphyrin IX (PpIX) is produced then activated by the introduction of a light source. Daylight-mediated MAL (methyl aminolaevulinate) PDT for AKs has the advantage of decreased pain and better patient tolerance. PDT is an effective treatment for superficial BCC, BD and both individual and field treatment of AKs. Excellent cosmesis can be achieved with high patient satisfaction. Variable results have been reported for nodular BCC, with improved outcomes following pretreatment and repeated PDT cycles. The more aggressive basisquamous, morphoeic infiltrating subtypes of BCC and invasive squamous cell carcinoma (SCC) are not suitable for PDT. Prevention of “field cancerization” in organ transplant recipients on long-term immunosuppression and patients with Gorlin syndrome (naevoid basal cell carcinoma syndrome) is a promising development. The optimisation of PDT techniques with improved photosensitiser delivery to target tissues, new generation photosensitisers and novel light sources may expand the future role of PDT in NMSC management.

show abstract

“…In one cohort study, 33 patients were treated with either topical PDT for superfi cial lesions (<2 mm thick) or systemic PDT for lesions >2 mm as assessed by ultrasound with overall local control rates of 56 % at 12 months (Loncaster et al 2009 ). In a case report of seven patients, including two children, treated with MAL-PDT, 60 % of lesions were cleared after one session and 78 % after three sessions (Girard et al 2013 ). MAL-PDT treatment also resulted in excellent cosmetic outcome.…”

Section: Nevoid Basal Cell Carcinoma Syndromementioning

confidence: 96%